Research Topics
| Flavio ForrerSummaryAffiliation: University Hospital Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
Neuroendocrine tumors. Peptide receptor radionuclide therapyFlavio Forrer
Department of Nuclear Medicine, Erasmus Medical Centre Rotterdam, Dr Molewaterplein 40, NL 3015 GD Rotterdam, The Netherlands
Best Pract Res Clin Endocrinol Metab 21:111-29. 2007..Furthermore, clinical issues--including indication and timing of therapy--are discussed. Finally, important directions for future research are mentioned to illustrate new strategies for increasing therapy efficacy...- A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumoursF Forrer
Institute of Nuclear Medicine, University Hospital, Petersgraben 4, 4031, Basel, Switzerland
Eur J Nucl Med Mol Imaging 31:1257-62. 2004.... - Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOCFlavio Forrer
Institute of Nuclear Medicine, University Hospital, Basel, Switzerland
J Nucl Med 46:1310-6. 2005..Trials with (177)Lu-labeled somatostatin analogs showed less nephrotoxicity. We initiated a prospective study with (177)Lu-DOTATOC in patients with relapsed neuroendocrine tumors after (90)Y-DOTATOC treatment... - Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumorsFlavio Forrer
Institute of Nuclear Medicine, University Hospital Basel, Switzerland
Anticancer Res 26:703-7. 2006..The aim of this study was to assess the efficacy and safety of targeted radionuclide therapy with [90Y-DOTA0, Tyr3]-octreotide (90Y-DOTATOC) in patients with metastatic neuroendocrine tumors... 
Is it possible to predict renal function in small animals using a multi-pinhole SPECT systemF Forrer
Eur J Nucl Med Mol Imaging 34:1127-8. 2007
Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotateFlavio Forrer
Department of Nuclear Medicine, Erasmus MC Rotterdam, Dr Molewaterplein 40, NL 3015 GD, Rotterdam, The Netherlands
Eur J Nucl Med Mol Imaging 36:1138-46. 2009..Also, we evaluated the absorbed cross-dose from the source organs (liver, spleen, kidneys and blood), tumours and the so-called "remainder of the body" to the bone marrow...- Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytomaF Forrer
Institute of Nuclear Medicine, University Hospital of Basel, Basel, Switzerland
Q J Nucl Med Mol Imaging 52:334-40. 2008..We evaluated the effectiveness and toxicity of radiolabeled DOTATOC in patients with metastatic paraganglioma and pheochromocytoma... - From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imagingFlavio Forrer
Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
Cancer Biother Radiopharm 22:40-9. 2007..We studied renal damage in rats after therapy with different amounts of [(177)Lu-DOTA(0), Tyr(3)]octreotate and investigated (99m)Tc-DMSA (dimercaptosuccinic acid) as a tool to quantify renal damage after PRRT... - In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animalsF Forrer
Department of Nuclear Medicine, Erasmus MC Rotterdam, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands
Eur J Nucl Med Mol Imaging 33:1214-7. 2006..In vivo quantification of radiopharmaceuticals has great potential as a tool in developing new drugs. We investigated the accuracy of in vivo quantification with multi-pinhole single-photon emission computed tomography (SPECT) in rats... 
Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumorsKeelara Abiraj
Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland
J Nucl Med 52:1970-8. 2011..The current study aims at developing clinically translatable bombesin antagonist-based radioligands for SPECT and PET of GRPr-positive tumors...- Tetraamine-derived bifunctional chelators for technetium-99m labelling: synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumoursKeelara Abiraj
Division of Radiological Chemistry, University Hospital of Basel, 4031 Basel, Switzerland
Chemistry 16:2115-24. 2010..The promising preclinical results of (99m)Tc-N4-BB-ANT warrant its potential candidature for clinical translation... - Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organsCristina Müller
Department of Nuclear Medicine, Erasmus MC Rotterdam, The Netherlands
Cancer Biother Radiopharm 22:151-9. 2007.... - Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotateEdgar J Rolleman
Department of Nuclear Medicine, Erasmus MC, s Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
Eur J Nucl Med Mol Imaging 34:763-71. 2007..We tested the cytoprotective drug amifostine, which selectively protects healthy tissue during chemo- and radiotherapy, for its renoprotective capacities after PRRT with high-dose [(177)Lu-DOTA(0),Tyr(3)]octreotate... - SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolateCristina Müller
Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
J Nucl Med 49:310-7. 2008..In this study SPECT/CT of FR-positive malignant and normal tissues and organs in mice was performed using an improved organometallic (99m)Tc-radiofolate... - Targeted radiotherapy with radiolabeled somatostatin analogsGuillaume Nicolas
Department of Radiology and Nuclear Medicine, University Hospital Basel, 4031 Basel, Switzerland
Endocrinol Metab Clin North Am 40:187-204, ix-x. 2011..This article reviews the effectiveness and safety of the different protocols and discusses several clinical algorithms used in an attempt to optimize targeted radiopeptide therapy... - Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumoursRosalba Mansi
Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland
Eur J Nucl Med Mol Imaging 38:97-107. 2011..We describe a new conjugate, RM2, with the chelator DOTA coupled to D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH(2) via the cationic spacer 4-amino-1-carboxymethyl-piperidine for labelling with radiometals such as (111)In and (68)Ga... - Dose-dependent effects of (anti)folate preinjection on 99mTc-radiofolate uptake in tumors and kidneysCristina Müller
Department of Nuclear Medicine, Erasmus MC, 3015 CE Rotterdam, The Netherlands
Nucl Med Biol 34:603-8. 2007..The aim of this study was to investigate the dose dependence of these effects and whether the same results could be achieved with folic acid (FA) or 5-methyl-tetrahydrofolate (5-Me-THF)... - In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry studyFlavio Forrer
Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
Eur J Nucl Med Mol Imaging 36:1443-52. 2009..DOTA-rituximab was prepared as a kit formulation and can be labelled in a short time (<20 min) with either (177)Lu or (90)Y... - Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclidesRosalba Mansi
Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland
Clin Cancer Res 15:5240-9. 2009..Here, we compare the new [111In/68Ga]-labeled bombesin-based antagonist RM1 with the agonist [111In]-AMBA for targeting the gastrin-releasing peptide receptor (GRPR)... - Short-term dietary restriction and fasting precondition against ischemia reperfusion injury in miceJames R Mitchell
Department of Genetics, Erasmus Medical Center, Cancer Genomics Center, Dr Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands
Aging Cell 9:40-53. 2010.... - Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P--results from a phase I studyDominik Cordier
Department of Neurosurgery, University Hospital Basel, Spitalstrasse 21, 4031, Basel, Switzerland
J Neurooncol 100:129-36. 2010..The high extent of resection and concomitant irradiation of tumor cells in the infiltration zone may be prognostically relevant... - Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapyGiampiero Giovacchini
Department of Radiology and Nuclear Medicine, Division of Endocrine Diagnostics and Radionuclide Therapy, University Hospital Basel, 4031, Basel, Switzerland
Eur J Nucl Med Mol Imaging 38:1675-82. 2011..However, the amino acid solution may have side effects, including hyperkalaemia. The aim of this study was to evaluate the frequency and the magnitude of hyperkalaemia in neuroendocrine tumour (NET) patients undergoing TRT... - Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trialD Cordier
Division of Neurosurgery, University Hospitals, Basel, Switzerland
Eur J Nucl Med Mol Imaging 37:1335-44. 2010..Therefore, we evaluated locally injected (213)Bi-DOTA-substance P in patients with critically located gliomas as the primary therapeutic modality... - Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapyM Melis
Department of Nuclear Medicine, Erasmus MC Rotterdam Rotterdam, The Netherlands
Q J Nucl Med Mol Imaging 51:324-33. 2007....